Chromomycosis: Chronic Skin Infection

Chromomycosis is a persistent fungal infection that affects the skin and underlying tissue, causing slow-growing warty lesions that can persist for years without treatment. Unlike many skin infections that heal within weeks, this condition develops gradually after fungi from soil or plant material enter through small wounds, most commonly on the legs and feet. The World Health Organization classifies chromomycosis as a neglected tropical disease, highlighting its significant impact on communities in tropical and subtropical regions where agricultural workers face the highest risk.

What causes chromomycosis 🔗

The infection results from specific pigmented fungi that naturally live in soil, decaying wood, and plant debris. Several dematiaceous fungi can cause this disease, with the most common being Fonsecaea pedrosoi, which accounts for the majority of cases in humid tropical areas. Other causative agents include Cladophialophora carrionii, Phialophora verrucosa, and Fonsecaea compacta. These fungi contain melanin-like pigments in their cell walls, giving them their characteristic dark appearance.

People typically contract the infection through traumatic inoculation when contaminated material enters the skin through minor injuries. Agricultural activities involving thorns, splinters, or contact with soil-contaminated surfaces create ideal conditions for fungal entry. Many patients cannot recall the initial injury since symptoms often do not appear for months or even years after the trauma.

Geographic distribution and at-risk populations 🔗

The infection occurs sporadically in tropical and subtropical climates, with the highest concentration of cases reported in Central and South America, Madagascar, and parts of Asia. Brazil, Costa Rica, Madagascar, and Venezuela have documented the most cases. The disease predominantly affects agricultural workers, farmers, and individuals who work barefoot in rural areas, with men between 30 and 50 years of age being the most commonly affected demographic.

While rare in the United States, cases have been reported, typically in immunocompromised individuals or those who have traveled to endemic regions. The global incidence remains unknown due to lack of systematic surveillance programs.

Clinical presentation and progression 🔗

The infection begins as a small pink or red papule at the inoculation site, usually on the lower extremities. This initial lesion is typically painless and may go unnoticed for extended periods. Over months to years, the infection slowly spreads, transforming into various morphologic forms including nodular, plaque-like, verrucous, or tumoral lesions.

Characteristic features include: Warty, cauliflower-like growths that can exceed 10 centimeters in diameter. Small dark spots visible on the surface of lesions represent clusters of pigmented fungal cells and serve as an important diagnostic clue. As the disease progresses, lesions may develop central scarring while the edges continue to spread. In advanced cases, severe limb swelling similar to elephantiasis can occur, significantly limiting movement and causing disability.

Complications of untreated disease 🔗

Without proper treatment, chromomycosis can lead to serious complications. Secondary bacterial infections frequently develop in longstanding cases, producing unpleasant odors and additional tissue damage. Severe limb swelling, lymphedema, and difficulty walking are common in advanced disease. In rare instances, squamous cell carcinoma can develop within chronic lesions, and the infection may spread through lymphatic channels or bloodstream to other organs, including the brain.

The physical disfigurement and disability caused by chromomycosis often lead to social stigma and exclusion, affecting patients’ ability to work and participate in community life.

Diagnosis through microscopic examination 🔗

The hallmark of chromomycosis diagnosis is identifying characteristic thick-walled, dark brown fungal cells in tissue samples. These structures, known as sclerotic bodies, medlar bodies, or muriform cells, appear as round, cigar-colored structures measuring 4-12 micrometers in diameter. These cells multiply by septation rather than budding, a key distinguishing feature from other fungal infections.

Diagnostic methods 🔗

Potassium hydroxide (KOH) preparation: The simplest diagnostic approach involves scraping material from the lesion, particularly from areas with visible black dots, and examining it under a microscope after KOH treatment. This often reveals the pathognomonic sclerotic bodies.

Histopathology: Skin biopsy provides definitive diagnosis, showing granulomatous inflammation with characteristic muriform cells in the dermis. The tissue demonstrates variable levels of fibrosis depending on disease duration and severity.

Culture: While useful for identifying the specific causative fungus, cultures grow slowly and may take one to two weeks to develop the characteristic olive-green to black colonies. Culture is not required to initiate treatment.

Treatment approaches and challenges 🔗

Oral antifungal medications form the cornerstone of treatment, with itraconazole and terbinafine showing the best results. Treatment typically requires 6-12 months for moderate cases, though extensive disease may need over a year of therapy. Early treatment within 3-6 months provides the best outcomes.

Medical management 🔗

First-line agents: Itraconazole at doses of 200-400 mg daily or terbinafine at 500 mg daily are most commonly prescribed. Some clinicians use combination therapy with both agents for more effective results in refractory cases. Voriconazole and posaconazole represent newer alternatives for difficult-to-treat infections.

Combination approaches: For extensive lesions, combining antifungal therapy with physical treatments often yields better outcomes. Cryotherapy with liquid nitrogen has shown particular promise when paired with oral antifungals. Other adjunctive therapies include local heat application, photodynamic therapy, and surgical excision for small, localized lesions.

Treatment challenges 🔗

Complete eradication of the infection proves difficult due to several factors. Tissue fibrosis resulting from chronic infection can reduce drug penetration to affected areas. Different fungal species show varying sensitivity patterns to antifungal agents. In endemic areas, the high cost of prolonged antifungal therapy often prevents patients from completing full treatment courses, leading to recurrence.

Prevention strategies 🔗

Preventing chromomycosis remains challenging since the causative fungi are ubiquitous in tropical environments. Wearing protective footwear, long pants, and gloves during agricultural work can reduce the risk of traumatic inoculation. Prompt cleaning and treatment of wounds sustained during outdoor activities may help prevent fungal establishment.

Early recognition and treatment are crucial for preventing severe disease and disability. Healthcare worker training and improved disease awareness in endemic regions can facilitate earlier diagnosis and intervention, ultimately improving patient outcomes and reducing long-term complications.

The importance of awareness 🔗

Chromomycosis represents a significant health burden in underserved communities where access to healthcare and antifungal medications remains limited. The disease’s slow progression and painless early stages often result in delayed diagnosis, making treatment more difficult and outcomes worse. Increased awareness among healthcare providers and at-risk populations can lead to earlier detection and better prognosis.

Understanding the characteristic features of this infection, including the diagnostic black dots on lesion surfaces and the slow, progressive nature of the disease, enables nurses and other healthcare workers to identify potential cases and refer patients for appropriate testing and treatment.

What do you think? How might improved access to protective equipment and healthcare education reduce the burden of chromomycosis in agricultural communities? What role can nurses play in early detection and patient education for this neglected tropical disease?

References

1. https://www.who.int/news-room/fact-sheets/detail/chromoblastomycosis
2. https://www.ncbi.nlm.nih.gov/books/NBK470253/
3. https://www.cdc.gov/chromoblastomycosis/about/index.html
4. https://emedicine.medscape.com/article/1092695-overview